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Neutralizing negative epigenetic regulation by
HDAC5 enhances human haematopoietic stem cell
homing and engraftment
Xinxin Huang1, Bin Guo1, Sheng Liu2, Jun Wan2 & Hal E. Broxmeyer1
Enhancement of hematopoietic stem cell (HSC) homing and engraftment is clinically critical,
especially for cord blood (CB) hematopoietic cell transplantation. Here we report that specific
HDAC5 inhibition highly upregulates CXCR4 surface expression in human CB HSCs and
progenitor cells (HPCs). This results in enhanced SDF-1/CXCR4-mediated chemotaxis and
increased homing to the bone marrow environment, with elevated SCID-repopulating cell
(SRC) frequency and enhanced long-term and secondary engraftment in NSG mice. HDAC5
inhibition increases acetylated p65 levels in the nucleus, which is important for CXCR4
transcription. Inhibition of nuclear factor-κB (NF-κB) signaling suppresses HDAC5-mediated
CXCR4 upregulation, enhanced HSC homing, and engraftment. Furthermore, activation of the
NF-κB signaling pathway via TNFα also results in significantly increased CXCR4 surface
expression, enhanced HSC homing, and engraftment. These results demonstrate a previously
unknown negative epigenetic regulation of HSC homing and engraftment by HDAC5, and
allow for a new and simple translational strategy to enhance HSC transplantation.
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Hematopoietic stem cells (HSCs) are the only cells that giverise to all blood cell lineages throughout life1. Allogeneichematopoietic cell transplantation (HCT) is a life-saving
therapy to treat patients with hematologic disorders and cancer2.
Human cord blood (CB) contains a life-saving source of HSC and
hematopoietic progenitor cell (HPC) for transplantation3,4.
However, limited numbers of HSC/HPC or poor homing are
problematic for efficient CB HCT5,6. Although extensive efforts
have been devoted to ex vivo expansion of HSCs aimed at facil-
itating HSC engraftments and clinical applications7–9, new
insights into intrinsic and extrinsic regulation of HSC migration/
homing will allow new strategies to improve HCT efficacy.
Intravenously transplanted HSCs migrate to the bone marrow
(BM) niche, where they are maintained and balanced with pro-
liferation and differentiation10,11. Stromal cell-derived factor-1
(SDF-1)/chemokine C-X-C receptor-4 (CXCR4) interactions are
implicated as a critical axis regulating HSC trafficking and
homing to the BM environment12,13. Modulating SDF-1/CXCR4
interactions of HSC/HPC can be used to improve the efficiency of
HSC homing. For example, Prostaglandin E2 (PGE2), cyclic
adenosine monophosphate, or glucocorticoid treatment facilitates
HSC homing by upregulating surface CXCR4 expression14–16,
whereas DPP4/CD26 inhibition enhances HSC homing and
engraftment via blockage of SDF-1 cleavage17, and mild hyper-
thermia promotes CXCR4 and lipid raft aggregation to enhance
HSC homing18.
Histone deacetylases (HDACs) are erasers of acetylation from
lysine residues and have important roles in many biological
processes, mainly through their repressive impacts on gene
transcription19. In mammals, HDACs comprise 18 genes that are
grouped into five subfamilies (class I, IIa, IIb, III, IV) based on
their sequence similarity20. HDAC5 belongs to class IIa HDACs,
which can shuttle between the cytoplasm and nucleus, assemble
into multiprotein complexes, and be responsive to various
environmental stimuli19,20. Previous studies have reported that
the functions of HDAC5 are associated with axon regeneration21,
muscle differentiation22, angiogenesis23, T-cell function24, and
cancer25–28. Of note, HDAC5-mediated deacetylation of signal
transducer and activator of transcription 3 (STAT3) has been
reported to regulate nuclear localization and transcriptional
activity of STAT3, resulting in changes of hypothalamic leptin
signaling and energy homeostasis29. However, the function of
HDAC5 in regulating HSC has not been investigated.
In the present study, we demonstrate that specific HDAC5
inhibition leads to upregulation of CXCR4 surface expression in
human CB HSCs and HPCs. Furthermore, we show that inhibi-
tion of HDAC5 results in increased SDF-1/CXCR4-mediated
chemotaxis and homing, with elevated in vivo engraftment.
Mechanistically, HDAC5 inhibition increases acetylated p65
levels associated with CXCR4 promoter region, whereas inhibi-
tion of nuclear factor (NF)-κB signaling suppresses both HDAC5-
mediated CXCR4 upregulation and enhanced HSC homing.
Moreover, activation of the NF-κB signaling pathway via tumor
necrosis factor-α (TNFα) also results in significantly increased
CXCR4 surface expression and enhanced HSC homing. Taken
together, these results suggest that HDAC5 negatively regulates
CXCR4 transcription and HSC homing via p65 acetylation. Our
observations allow for a new and simple translational strategy to
enhance HSC transplantation-based therapies.
Results
Inhibition of HDAC enhances CB HSC homing and engraftment.
We hypothesized that epigenetic regulations contribute to the
expression of CXCR4 receptor and HSC homing. To identify new
epigenetic regulators of CXCR4 receptor expression, we screened
a chemical compound library of epigenetic enzyme inhibitors to
evaluate their effects on membrane CXCR4 expression in CB
CD34+ cells. Treatment of CB CD34+ cells for 16 h with a
HDAC inhibitor, M344, strongly upregulated membrane CXCR4
expression (Fig. 1a and Supplementary Fig. 1a). Confocal imaging
and flow cytometry analysis both revealed that M344 treatment
strongly increased membrane CXCR4 expression compared with
vehicle control (Fig. 1b–d). In addition, expression of membrane
CXCR4 on CB CD34+ cells was enhanced after treating cells with
other HDAC inhibitors, including Vorinostat, Trichostatin A,
and Belinostat (Supplementary Fig. 1b). The effect of M344 in
a rigorously defined population of HSCs (CD34+CD38
−CD45RA−CD49f+CD90+) was associated with a 2.5-fold
increase in surface CXCR4 expression (Fig. 1e). M344 also
enhanced surface expression of CXCR4 on multipotent progeni-
tors (MPPs, CD34+CD38−CD45RA− CD90−CD49f−), CD34
+CD38−CD90+, and CD34+CD38− cells (Supplementary
Fig. 1c-e). In contrast, the surface expression of CD49d/CD29
(VLA-4), also involved in HSC migration and homing30, was not
changed after M344 treatment (Supplementary Fig. 1f, g).
The effect of HDAC inhibition on HSC chemotaxis was
evaluated in an in vitro transwell migration assay. Both vehicle
and M344-treated CB CD34+ cells showed significant migration
to SDF-1; however, chemotaxis was notably higher in the M344-
treated group (Fig. 1f). Enhanced migration to SDF-1 by M344
was also observed in the HSC population (Fig. 1g). Chemotaxis of
CB CD34+ cells to SDF-1 was blocked by CXCR4 antagonist
AMD310031, suggesting that the enhanced migration was
mediated through CXCR4 (Fig. 1f). To evaluate in vivo homing,
vehicle and M344-treated CB CD34+ cells were injected into
sublethally irradiated NSG mice and human cell homing to
mouse BM and spleen were analyzed 24 h after transplantation.
M344 treatment enhanced CB CD34+ cells homing in both BM
and spleen in NSG mice (Fig. 1h).
Long-term engraftment of human CB CD34+ cells was
assessed by limiting dilution assay to compare frequencies of
SCID-repopulating cells (SRCs) in vehicle and M344-treated CB
CD34+ cells. M344-treated CB CD34+ cells manifested signifi-
cantly greater engraftment in primary NSG recipient mice
compared with that of the vehicle control-treated group (Fig. 2a,
b). Human myeloid and B-cell chimerisms were also significantly
increased (Fig. 2b). Poisson distribution analysis revealed an SRC
frequency of 1/3216 for the vehicle control-treated group and 1/
746 for the M344-treated group. This reflected respectively 311
and 1341 SRCs in 1 × 106 cells from vehicle control and M344-
treated cultures, resulting in a 4.3-fold increase in the number of
functionally detectable SRCs compared with the vehicle control
group (Fig. 2c, d and Supplementary Table 1, 2). To evaluate self-
renewal capability, we transplanted BM cells from primary NSG
recipient mice into secondary sublethally irradiated NSG mice.
The M344-treated group resulted in greater engraftment in
transplanted secondary recipients (Fig. 2e), suggesting we had
increased engraftment of long-term self-renewing human CB
HSCs after M344 treatment.
HDAC5 inhibition promotes CB HSC homing and engraft-
ment. Eighteen HDACs divided into four classes have been
identified in humans20,32. Mechanisms regarding HDAC regula-
tion of HSC homing and engraftment are largely unknown. Using
short hairpin RNA to knockdown expression of individual
HDACs in CB CD34+ cells (Supplementary Fig. 2), we surpris-
ingly found that only HDAC5 shRNA transfection resulted in
upregulation of membrane CXCR4 expression (Fig. 3a). Flow
cytometry and confocal imaging analysis revealed increased
membrane CXCR4 expression by LMK23533, a selective inhibitor
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of HDAC5 (Fig. 3b–d and Supplementary Fig. 3a). In contrast,
inhibition of other HDACs showed no effects on membrane
CXCR4 expression in CB CD34+ cells (Supplementary Fig. 3b).
Similar to M344, HDAC5 inhibition by LMK235 resulted in
significantly higher membrane CXCR4 expression in CB HSCs,
MPPs, CD34+CD38−CD90+, and CD34+CD38− cells (Supple-
mentary Fig. 3c-f). We also examined the expression of HDAC5
and found that HDAC5 is highly expressed in CB HSCs (Sup-
plementary Fig. 3g, h), suggesting a potential important role of
HDAC5 in HSCs.
We next assessed whether HDAC5 inhibition can promote
chemotaxis of CB HSCs toward SDF-1. LMK235 treatment
significantly enhanced chemotaxis of CB CD34+ cells toward
SDF-1, which can be fully blocked by CXCR4 antagonist
AMD3100 (Fig. 3e). Enhanced migration to SDF-1 by LMK235
was also observed in the HSC population (Fig. 3f). We then tested
whether HDAC5 inhibition enhanced homing in vivo. Human
CB CD34+ cells were treated with vehicle and LMK235 for 16 h
and transplanted into sublethally irradiated NSG mice, we found
that LMK235 treatment greatly increased the homing efficiency of
CB CD34+ cells (Fig. 3g). To further demonstrate that the homed
cells contain self-renewing HSCs, we collected BM cells from
primary NSG recipients used in the homing assay and injected
them into secondary recipients to check for long-term
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Fig. 1 Inhibition of HDAC upregulates surface CXCR4 expression and promotes homing of human hematopoietic stem and progenitor cells. a Mean
fluorescence intensity (MFI) of surface CXCR4 of human CB CD34+ cells after treating cells for 16 h with compounds (1 μM) from the SCREEN-WELL
Epigenetics Library. One compound, BML-266, was excluded from the results because of unspecific autofluorescence. b Histogram of surface CXCR4
expression of human CB CD34+ cells treated with vehicle or HDAC inhibitor M344. Representative histogram from five independent experiments is
shown. c Quantification of mean fluorescence intensity (MFI) of surface CXCR4 of human CB CD34+ cells treated with vehicle or HDAC inhibitor M344.
None indicates the group without any treatment. Data pooled from five independent experiments are shown (n= 5, one-way ANOVA, ***p < 0.001).
d Confocal imaging analysis of surface CXCR4 expression of human CB CD34+ cells treated with vehicle or M344. FITC (green) indicates CXCR4
expression; DAPI (blue) labels the cell nucleus. Representative images from two independent experiments are shown (the inset shows the amplified part of
the image). Scale bar: 20 μm. e Quantification of mean fluorescence intensity (MFI) of surface CXCR4 of human CB HSCs (CD34+CD38−CD45RA−CD90
+CD49f+) treated with vehicle or M344. None indicates the group without any treatment. Data pooled from five independent experiments are shown (n=
5, one-way ANOVA, ***p < 0.001). f Chemotaxis of human CB CD34+ cells toward human recombinant SDF-1, as quantified by flow cytometry. Data
pooled from three independent experiments are shown (each dot represents an independent chemotaxis, n= 3 CB samples, one-way ANOVA, **p < 0.01,
***p < 0.001). g Migration of human phenotypic HSCs in CB CD34+ cells toward human recombinant SDF-1 (50 ng/mL), as quantified by flow cytometry.
The migration percentage of HSCs was calculated by analyzing the HSC (CD34+CD38−CD45RA−CD90+CD49f+) frequency using flow cytometry. Data
pooled from three independent experiments are shown (each dot represents an independent chemotaxis, n= 3 CB samples, t-test, **p < 0.01). h The
percentage of human CD45+ cells in the BM and spleen of NSG mice 24 h after transplantation with 500,000 CB CD34+ cells that had been treated with
vehicle or M344. Data pooled from seven independent experiments are shown (n= 7 mice per group, t-test, **p < 0.01, ***p < 0.001). For all panels, data
are shown as dot plots (mean ± SEM)
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engraftment. We found that LMK235-treated CD34+ cells also
showed increased engraftment in these transplanted secondary
recipients (Fig. 3h), suggesting LMK235 treatment promoted
homing of self-renewing CB HSCs.
Next we performed limiting dilution assay to compare the
frequency of SRCs for vehicle and LMK235-treated CB CD34+
cells. Engraftment of LMK235-treated CB CD34+ cells was
largely elevated in primary NSG recipient mice, compared with
the vehicle control-treated group (Fig. 4a, b). Human myeloid
and B-cell chimerisms were also significantly increased (Fig. 4b).
The SRC frequency was 1/7916 in vehicle control-treated CB
CD34+ cells with an increased SRC frequency of 1/1326 in
LMK235-treated cells, with 126 and 754 SRCs, respectively, in
1 × 106 cells from vehicle control- and LMK235-treated cells,
demonstrating a 6.0-fold increase in numbers of functionally
detectable SRCs compared with vehicle control (Fig. 4c, d and
Supplementary Tables 3, 4). LMK235-treated CB CD34+ cells
also showed increased engraftment in transplanted secondary
recipients (Fig. 4e). Thus, HDAC5 inhibition enhances engraft-
ment of long-term repopulating, self-renewing human CB HSCs.
HDAC5 inhibition promotes CXCR4 transcription. HDACs
regulate gene transcription by modifying histone and chromatin
structures20. Quantitative reverse transcription-PCR showed
increased CXCR4 messenger RNA levels in both M344 and
LMK235-treated CB CD34+ cells compared with vehicle control
(Fig. 5a). The levels of CXCR4 mRNA also increased in HDAC5
knockdown CB CD34+ cells, indicating that HDAC5 inhibition
promotes CXCR4 expression at a transcriptional level (Fig. 5b).
Chromatin immunoprecipitation (ChIP) assays examined chro-
matin status at the CXCR4 promoter region. Acetylation levels on
histone 3 lysine 9 (H3K9) and histone 4 lysine 16 (H4K16) were
significant higher in both M344- and LMK235-treated CB CD34+
cells compared with vehicle control, suggesting that increased
histone acetylation levels at the CXCR4 promoter region con-
tributes to increased CXCR4 transcription (Fig. 5c, d). The action
of histone acetyltransferase is opposite to that of HDACs34, so we
tested effects of histone acetyltransferase p300 inhibitor, C646, on
surface expression of CXCR4 in CB CD34+ cells. Treatment of
CB CD34+ cells with C646 suppressed effects of M344 and
LMK235 on CXCR4 expression (Fig. 5e). Another p300 inhibitor,
EML425 showed similar suppressive effects on CXCR4 surface
expression in CB CD34+ cells treated with M344 and LMK235
(Supplementary Fig. 4a). This suggests that a balance between
histone acetyltransferase and deacetylase is important for CXCR4
expression in CB CD34+ cells.
Transcriptome analysis after HDAC5 inhibition. To gain fur-
ther insight into the effects of HDAC5 inhibition, we performed
RNA sequencing (RNA-seq) on LMK235- and vehicle-treated CB
CD34+ cells. As expected, CXCR4 was identified as one of the
positive hits (Fig. 5f). Consistent with the reports showing that
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Fig. 2 Inhibition of HDAC promotes long-term engraftment of human CB HSC. a Representative flow cytometric analysis of human engraftment in the BM
of NSG mice, 16 weeks after transplantation. Left is from a mouse without transplantation (negative control), center and right are from mice transplanted
with human CB CD34+ cells treated with vehicle control or M344 for 16 h. Human engraftment was assessed as the percentage of human CD45+ cells.
b The percentage of human CD45+ cells, B-cell (CD19+), and myeloid cell (CD33+) chimerism in the BM of NSG mice after transplantation with 10,000
CB CD34+ cells that had been treated with vehicle or M344. The data were pooled from two independent experiments (n= 10 mice for vehicle group, n=
9 for M344 group, t-test, **p < 0.01). c, d The frequency of human SRCs in CB CD34+ cells treated with vehicle control or M344. c Poisson statistical
analysis of data from Supplementary Table 1. n= 30 mice in total. Shapes represent the percentage of negative mice for each dose of cells. Solid lines
indicate the best-fit linear model for each data set. Dotted lines represent 95% confidence intervals. d HSC frequencies (line in the box) and 95%
confidence intervals (box) presented as the number of SRCs in 1 × 106 CD34+ cells. Poisson statistical analysis, *p < 0.05. e Human CD45+ cell chimerism
in the BM of secondary recipient NSG mice at 16 weeks, which had been transplanted with 5 × 106 BM cells from primary recipient NSG mice (n= 5 mice
per group, t-test, *p < 0.05). For all panels, data are shown as dot plots (mean ± SEM)
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PGE2 promotes HSC homing15, we identified that PTGER4, a
PGE2 receptor, has a strong enrichment in LMK235-treated CB
CD34+ cells (Fig. 5f). Gene ontology (GO) analysis revealed an
upregulation of gene sets linked with cell locomotion, cell moti-
lity, cell migration, and cell adhesion, all of which have been
reported to be involved in HSC homing (Fig. 5g). Cytoskeleton
rearrangements have been shown to be crucial during HSC
homing process35,36. GO analysis also showed a significant
enrichment of transcripts associated with cytoskeleton and
cytoskeleton-binding proteins in LMK235-treated CB CD34+
cells (Fig. 5g). These transcriptomic data provide additional
evidence supporting that HDAC5 modulates HSC homing
through transcriptional regulation.
HDAC5 regulates levels of p65 acetylation. NF-κB signaling and
NF-κB subunit p65 regulate CXCR4 expression in breast cancer
cells and neuroblastoma37,38, and acetylation of p65 at lysine 310
(K310) regulates its DNA-binding activity and target gene
transcription39,40. We hypothesized that HDAC5 regulates p65
acetylation to promote CXCR4 expression and HSC homing. We
then examined the levels of p65 acetylation and found that p65
M
FI
 o
f s
ur
fa
ce
 C
XC
R4
CD34+ cells
***
Vehicle
LMK235
APC-A
CXCR4
a b c
**
Fo
ld
 c
ha
ng
e 
of
 s
ur
fa
ce
 C
XC
R4
LMK235Vehicle
%
 o
f h
um
an
 C
D3
4+
 
m
ig
ra
tio
n Vehicle
LMK235
***
0 25 50 50 + AMD3100
SDF-1 (ng/mL)
***
0
20
40
60
***
%
 o
f h
um
an
 C
D4
5+
 
ce
lls
BM Spleen
***
**
0.00
0.05
0.10
0.15
0.20
0.25
%
 o
f H
SC
 m
ig
ra
tio
n
**
0
20
40
60
80
Vehicle LMK235
d e
f g h
shH
DA
C1
shH
DA
C2
shH
DA
C3
shH
DA
C4
shH
DA
C5
shH
DA
C6
shH
DA
C7
shH
DA
C8
0.0
0.5
1.0
1.5
2.0
2.5
No
ne
Ve
hic
le
LM
K2
35
Ve
hic
le
LM
K2
35
Ve
hic
le
LM
K2
35
Ve
hic
le
LM
K2
35
0
50
100
150
200
Co
un
ts
%
 o
f h
um
an
 C
D4
5 
ch
im
er
ism
 in
BM
 o
f s
ec
on
da
ry
 re
cip
ie
nt
s *
0
10
20
30
100
80
60
40
20
0
100 101 102 103 104
Fig. 3 Inhibition of HDAC5 enhances CB HSC homing by upregulating CXCR4 surface expression. a Fold change of mean fluorescence intensity of surface
CXCR4 of human CB CD34+ cells after transfecting cells with indicated shRNA for individual HDACs. Individual shRNA knockdown efficiency was shown
in Supplementary Fig. 2. Data pooled from three independent experiments are shown (n= 3, t-test, **p < 0.01). b Histogram of surface CXCR4 expression
of human CB CD34+ cells treated with vehicle or HDAC5 inhibitor LMK235. Representative histogram from five independent experiments is shown.
c Quantification of mean fluorescence intensity (MFI) of surface CXCR4 of human CB CD34+ cells treated with vehicle or HDAC5 inhibitor LMK235. None
indicates the group without any treatment. Data pooled from five independent experiments are shown (n= 5, one-way ANOVA, ***p < 0.001). d Confocal
imaging analysis of surface CXCR4 expression of human CB CD34+ cells treated with vehicle or LMK235. Green indicates CXCR4 expression; DAPI (blue)
labels the cell nucleus. Representative images from two independent experiments are shown (the inset shows the amplified part of the image). Scale bar:
20 μm. e Human CB CD34+ cells migration toward human recombinant SDF-1, as quantified by flow cytometry. Data pooled from three independent
experiments are shown (each dot represents an independent chemotaxis, n= 3 CB samples, one-way ANOVA, ***p < 0.001). f Migration of human
phenotypic HSCs in CB CD34+ cells toward human recombinant SDF-1 (50 ng/mL), as quantified by flow cytometry. Data pooled from three independent
experiments are shown (each dot represents an independent chemotaxis, n= 3 CB samples, t-test, **p < 0.01). g The percentage of human CD45+ cells in
the BM and spleen of NSG mice 24 h after transplantation with 500,000 CB CD34+ cells that had been treated with vehicle or LMK235. Data pooled from
seven independent experiments are shown (n= 7 mice per group, t-test, **p < 0.01, ***p < 0.001). h The percentage of human CD45+ cells in the BM of
secondary recipient NSG mice that were transplanted with BM cells from primary mice used in the homing assay (n= 5 mice per group, t-test, *p < 0.05).
For all panels, data are shown as dot plots (mean ± SEM)
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acetylation at K310 was markedly increased in CB CD34+ cells
with M344 and LMK235 treatment (Fig. 6a, b). Treatment of CB
CD34+ cells with C646 suppressed effects of M344 and LMK235
on p65 acetylation (Fig. 6b). Confocal imaging analysis confirmed
elevated p65 acetylation in the nucleus of CB CD34+ cells with
M344 and LMK235 treatment (Fig. 6c). p65 expression levels
were unaltered in M344 and LMK235 compared with vehicle
control-treated CB CD34+ cells (Supplementary Fig. 4b), sug-
gesting that regulation of p65 by HDAC5 is posttranslational.
Using ChIP assay we detected increased levels of acetylated p65
binding to the CXCR4 promoter region in the LMK235-treated
group compared with vehicle control (Fig. 6d). We next investi-
gated whether HDAC5 physically interacted with p65. Indeed, we
found that HDAC5 immunoprecipitated with acetylated p65
(Fig. 6e). Taken together, these results suggest HDAC5 interacts
with p65 and regulates its acetylation, which potentially upre-
gulates CXCR4 transcription.
Inhibition of NF-κB signaling suppresses HSC homing. To
further confirm the role of NF-κB signaling in HSC homing, we
next evaluated effects of NF-κB inhibition on surface expression
of CXCR4 and CB HSC homing. Inhibition of the NF-κB sig-
naling pathway by Andrographolide, BMS345541, or Pyrrolidi-
nedithiocarbamate ammonium (PDTC) repressed effects of M344
and LMK235 on CXCR4 upregulation (Fig. 7a, b and Supple-
mentary Fig. 5a). Andrographolide or BMS345541 treatment also
suppressed SDF-1/CXCR4-mediated CB CD34+ cell chemotaxis
(Fig. 7c and Supplementary Fig. 5b). Next we assessed the effects
of NF-κB inhibition in vivo. Inhibition of the NF-κB signaling
pathway by Andrographolide blocked enhanced homing of
LMK235-treated CB CD34+ cells (Fig. 7d and Supplementary
Fig. 5c). We followed long-term engraftment and confirmed that
Andrographolide also suppressed LMK235-mediated increases of
human cell chimerism in primary recipient mice (Fig. 7e, f). Our
data indicate that inhibition of NF-κB signaling suppresses the
effects of HDAC5 inhibition on CXCR4 upregulation, increased
HSC homing, and engraftment.
TNFα treatment results in enhanced HSC homing. TNFα
activates canonical NF-κB signaling41. We found significant
upregulation of surface CXCR4 expression after TNFα treatment
in CB CD34+ cells, effects suppressed by inhibitors of the NF-κB
signaling pathway (Fig. 8a). The levels of CXCR4 mRNA also
increased after TNFα treatment in CB CD34+ cells (Supple-
mentary Fig. 6a). Moreover, TNFα treatment significantly
enhanced chemotaxis towards SDF-1 and in vivo homing
(Fig. 8b, c). Inhibition of the NF-κB pathway by Andro-
grapholide blocked effects of TNFα-enhanced homing in vivo
(Fig. 8c and Supplementary Fig. 6b). Long-term engraftment of
human CB CD34+ cells was assessed in primary recipients
transplanted with vehicle and TNFα-treated CB CD34+ cells.
TNFα-treated CB CD34+ cells showed significantly elevated
engraftment in NSG mice compared with that of the vehicle
control-treated group (Fig. 8d, e). Human myeloid and B-cell
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chimerisms were also increased (Fig. 8e). Thus, activation of
NF-κB signaling is sufficient to promote surface expression
of CXCR4 and enhance homing and engraftment of CB
CD34+ cells.
Discussion
HSC homing efficiency is a pivotal factor for a successful HCT-
based clinical therapy. In this work, we show that upon HDAC5
inhibition, acetylated p65 binds to the CXCR4 promotor region,
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transcriptionally upregulates CXCR4 surface expression and
enhances homing and long-term engraftment of self-renewing
human CB HSCs (Fig. 9). Our study could lead to significant
improvements particularly for CB transplantation, where limited
HSC numbers presented in each single unit create clinical
limitations.
It has been reported that HDAC inhibition promotes HSC
ex vivo expansion and enhances engraftment42,43. However, the
role of HDAC in HSC homing and the underlying mechanism
were largely unknown. We now demonstrate, for the first time,
that HDAC5 inhibition facilitates HSC engraftment by upregu-
lating surface CXCR4, enhancing chemotaxis to SDF-1 and
homing to the BM. HDAC inhibition has been shown to alter
CXCR4 expression in various cell types and it seems the regula-
tion could be either positive or negative depending on cell con-
text. HDAC inhibition decreased surface CXCR4 expression in
dendritic cells, CD4 T cells, and monocytes44,45, whereas inhi-
bition of HDAC promoted surface CXCR4 expression in
mesenchymal stem cells46 and HSCs (this study). It would be
interesting to explore what kind of cell-type-specific factors
cooperated with which specific HDAC to regulate CXCR4
expression in various types of cells.
HDAC5 belongs to the class IIa HDAC family and has been
known to shuttle between the cytosol and the nucleus20. HDAC5
phosphorylation can be regulated by external signals, which
would promote HDAC5 shuttling to the cytosol and relieve its
transcription suppressive function. Thus, the regulation of
HDAC5 provides a mechanism for linking extracellular signaling
with HSC migration/homing to the BM environment. In the
original work by Marek et al.33, LMK235 showed the highest
activity at HDAC5 in the nanomolar range. However, they used
in vitro activity assay to detect the efficiency of LMK235. To
target the intracellular HDAC5 when treating cells, we believe
that higher concentration of LMK235 will be needed. Also dif-
ferent cell types will be different in their capability to take up the
compound. We performed titration on LMK235 for human CB
CD34+ cells and determined that 1 μM worked best (Supple-
mentary Fig 3a). Thus, we used 1 μM to treat human CB CD34+
cells for in vivo and mechanistic studies.
NF-κB signaling pathway is well documented in inflammatory
responses and TNFα is an inflammatory cytokine that activates
NF-κB signaling41. Our data show for the first time that NF-κB
signaling is involved in HSC homing to the BM microenviron-
ment. Inhibition of NF-κB signaling suppressed the effects of
HDAC5 inhibitor on CXCR4 upregulation and enhanced HSC
homing, whereas activation of NF-κB signaling by TNFα pro-
moted CXCR4 expression and HSC homing. The crosstalk
between NF-κB signaling and HSC homing has a physiologic
implication that HSC could be protected by activating NF-κB
signaling to migrate to the BM niche during inflammation and
infection. Furthermore, it has been reported that genetic deletion
of NF-κB subunit p65 severely impairs HSC function47. Con-
sistently, we found that p65 is involved in CXCR4 transcription in
CB HSC and mediated HDAC5 function.
Collectively, our findings have significant translational impli-
cations. Short-term ex vivo treatment of cells with M344,
LMK235, or TNFα has the potential to greatly improve the
clinical efficacy of CB transplantation, especially for the use of
single CB unit for adult transplantation. Moreover, as higher
expression of CXCR4 by cancer cells is associated with metastatic
migration48, our study suggests that it might be clinically feasible
to inhibit tumor cell migration by targeting HDAC5.
Methods
Mice. Six to eight weeks old NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/Sz) mice were
obtained from the In Vivo Therapeutics Core of the Indiana University School of
Medicine (IUSM). All experimental protocols with mice were approved by The
Institutional Animal Care and Use Committee of IUSM.
Isolation and culture of CB CD34+ cells. Isolation of CD34+ cells from normal
human CB samples (CordUse, Orlando, FL, USA) was performed by density
gradient centrifugation over Ficoll Paque Plus (GE Healthcare, Piscataway, NJ,
USA) and collection through an human CD34 MicroBead Kit (Miltenyi Biotec, San
Diego, CA, USA)9,16,49. CD34+ cells were then cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum, 100 ng/mL stem cell factor (7466-SC-
010/CF, R&D Systems, Minneapolis, MN, USA), thrombopoietin (288−TP-200/CF,
R&D Systems), and Fms-like tyrosine kinase 3 ligand (Flt3L) (# 710802, BioLe-
gend). For small molecule compound screen, 50,000 CD34+ cells were cultured in
the above medium with compounds (1 μM) from the SCREEN-WELL Epigenetics
Library (Enzo Life Sciences, Farmingdale, NY, USA) for 16 h. For treatment of
HDAC inhibitors, the cells were incubated with M344 (S2779, 1 μM) or LMK235
(S7569, 1 μM) (Selleck Chemicals, Houston, TX, USA) for 16 h unless otherwise
stated. The following compounds were also used: C646 (Selleck Chemicals, 50 μM),
EML425 (Tocris Bioscience, 50 μM), Andrographolide (Tocris Bioscience, 10 μM),
BMS345541 (Tocris Bioscience, 10 μM), and PDTC (Tocris Bioscience, 20 μM).
Dimethyl sulfoxide (D2650, Sigma-Aldrich, St. Louis, MO, USA) was used as
vehicle control.
Immunostaining and flow cytometry. Samples were washed and stained with
antibodies at 4 °C for 30 min. Then cells were washed with 1 mL phosphate-
buffered saline (PBS) and resuspended in 1% formaldehyde buffer before analysis.
For intracellular staining, cells were first fixed and permeabilized using a Cell
Permeabilization Kit (BD Biosciences, San Jose, CA, USA) before incubating with
primary and secondary antibodies. The following antibodies from BD Bioscience
were used for cell surface staining in 1:100 dilution: CD34-FITC (581), CD38-PE
(HIT2), CXCR4-APC (12G5), CD45RA−PE-CF594 (HI100), CD49f-PerCPcy5.5
(GoH3), CD90-PEcy7 (5E10), CD49d-APC (9F10), CD29-PE (MAR4), CD45-APC
(HI30), CD19-PE (HIB19), and CD33-PEcy7 (WM53). The following antibodies
were used for intracellular staining in 1:100 dilution: anti-p65 acetyl K310
(ab19870, Abcam, Cambridge, MA, USA), anti-p65 (ab32536, Abcam). Flow
cytometry analysis was performed on an LSRII flow cytometer (BD Biosciences).
shRNA knockdown assay. For HDAC knockdown, shRNA expression plasmids
(psi-LVRU6GP, obtained from Genecopeia) targeting HDAC1-HDAC8 were
transfected into CB CD34+ cells by nucleofection (Amaxa™ Nucleofector™ Tech-
nology) following Lonza’s optimized protocols (Lonza, VPA-1003). After trans-
fection, cells were cultured for 48 h and CXCR4 expressions were determined by
surface staining and followed by flow cytometry analysis.
Fig. 5 Inhibition of HDAC5 promotes CXCR4 transcription. a CXCR4mRNA levels in M344- or LMK235-treated human CB CD34+ cells, relative to vehicle-
treated cells, as assessed by quantitative RT-PCR. None indicates the group without any treatment. Data pooled from two independent experiments
are shown (n= 6, one-way ANOVA, ***p < 0.001). b Human CB CD34+ cells were transfected with scrambled control or HDAC5 shRNA plasmids,
then CXCR4 mRNA levels were analyzed by quantitative RT-PCR. Data pooled from two independent experiments are shown (n= 6, t-test, **p < 0.01).
c, d Acetylated H3K9 (Ac-H3K9, b) and H4K16 (Ac-H4K16, c) levels on CXCR4 promoter in vehicle, M344-, or LMK235-treated human CB CD34+ cells, as
assessed by ChIP assays. Data pooled from two independent experiments are shown (n= 6, one-way ANOVA, ***p < 0.001). e Mean fluorescence
intensity (MFI) of surface CXCR4 in vehicle, C646 (50 μM), M344-, M344+ C646-, LMK235-, LMK235+C646-treated human CB CD34+ cells, as
assessed by flow cytometry. Data pooled from two independent experiments are shown (n= 5, one-way ANOVA, ***p < 0.001, NS indicates p > 0.05).
f Heatmap of upregulated differentially expressed genes (DEGs) associated with “cell migration” whose average count-per-million (CPM) larger than 8 in
vehicle control group (details described in Methods section). D1, D2, D3 represent three vehicle control-treated groups; K1, K2, K3 represent three
LMK235-treated groups (n= 3 CB samples). g Selected GOs that are significantly enriched and showed upregulated expression in LMK235-treated group
compared with vehicle control group. For all panels, data are shown as mean ± SEM
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Confocal imaging. M344-, LMK235-, or vehicle-treated CB CD34+ cells were
placed on a Nunc glass dish (150680, Thermo Fisher Scientific) coated with poly-L-
lysine. Immunostainings were performed using anti-CXCR4 (ab124824) or anti-
p65 acetyl K310 (ab19870, Abcam) in 1:100 dilution at room temperature for 20
min followed by fluorecein isothiocyanate (FITC)-labeled secondary antibodies.
Samples were washed with PBS and resuspended with buffer containing DAPI
(Vector Laboratories), and visualized using an Olympus FV-1000 confocal
microscope.
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Chemotaxis assay. Chemotaxis assays were performed by using Costar 24-well
transwell plates with 6.5 mm diameter inserts with 5.0 μm pores (Corning, Inc.,
Corning, NY, USA). 650 μL of pre-warmed IMDM medium (37 °C) that contained
0.5% bovine serum albumin (Sigma-Aldrich) and SDF-1 (0, 25, 50 ng/mL) was
added to the bottom well. Cells were suspended at 1 × 105 cells/100 μL in IMDM
medium and loaded to the upper chamber of the transwell. Transwell plates were
placed in a 37 °C incubator with 95% humidity and 5% CO2for 4 h. Percent
migration was measured using flow cytometry with number of cells in the bottom
chamber divided by number of cells placed in the upper chamber. To calculate
percent migration of CB HSCs, phenotypic HSCs(CD34+CD38−CD45RA−CD90+
CD49f+ cells) was determined by surface staining and flow cytometry analysis.
Human CB HSC chemotaxis was calculated as number of HSCs in the bottom
chamber divided by number of HSCs loaded in the upper chamber. For AMD3100
administration, cells were treated with 5 μg/mL AMD3100 (239820, Sigma-
Aldrich) for 30 min right before the chemotaxis assay.
In vivo homing assay. Homing of human CB CD34+ cells were evaluated in NSG
mice. M344-, LMK235-, or vehicle control-treated CB CD34+ cells (500,000 for
each mouse) were intravenously injected into sublethally irradiated (350 cGy) NSG
mice. After 24 h, these recipient mice were sacrificed, BM and spleen cells from
each mouse were collected. Cells were stained with anti-human CD45 antibody,
then resuspended in 1% formaldehyde buffer. Flow cytometry analysis was per-
formed to determine the percentage of human CD45+ cells. BM and spleen cells
from non-transplanted NSG mice were served as the negative control.
Limiting dilution analysis. Limiting dilution analysis was performed to calculate
the frequency of human SRCs in different experimental groups16,49. Briefly,
increasing doses of M344-, LMK235-, or vehicle control-treated CB CD34+ cells
(500, 2500, or 10,000 cells) were intravenously transplanted into sublethally irra-
diated (350 cGy) NSG mice. Sixteen weeks after transplantation, BM cells were
collected and human CD45+ cell, B-cell, and myeloid cell chimerism was evaluated
by immunostaining and flow cytometry analysis. For the secondary engraftment
and assessment of self-renewal activity, 5 × 106 BM cells from the primary NSG
recipient mice were injected into secondary NSG recipients. The HSC frequency
was calculated using L-Calc software (Stem Cell Technologies Inc, Vancouver, BC,
Canada) and plotted using ELDA software (bioinf.wehi.edu.au/software/elda/).
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TNFα (TNF, 100 ng/mL), Andrographolide (Andro)-, TNF+Andro-, BMS345541 (BMS)-, TNF+ BMS-treated human CB CD34+ cells, as assessed by flow
cytometry. None indicates the group without any treatment. Data pooled from three independent experiments are shown (n= 6, one-way ANOVA, ***p <
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were also shown. Data pooled from three independent experiments are shown (n= 3, one-way ANOVA, ***p < 0.001). c The percentage of human CD45+
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Fig. 9 Model for the role of HDAC5 in regulating CXCR4 expression in
human HSC/HPCs. HDAC5 inhibition by LMK235 results in enhanced
acetylation of histone 3 on lysine 9 and histone 4 on lysine 16, as well as
p65 acetylation. Acetylation of histone facilitates chromatin remodeling,
whereas acetylation of p65 enhances its transcriptional activity. Acetylated
p65 binds to CXCR4 promoter region and induces higher expression of
CXCR4 and thus enhances HSC/HPC homing and engraftment
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ChIP assay. ChIP was conducted using an EZ-ChIP kit following the manu-
facturer’s instructions (17-371, EMD Millipore, Billerica, MA, USA)16. In brief,
vehicle control-, M344-, or LMK235-treated CB CD34+ cells were fixed in 1%
formaldehyde for 10 min, and then lysed, sonicated, and incubated with specific
antibodies, followed by precipitation using protein G agarose beads. Then enriched
chromatin DNA was isolated and subjected to quantitative real-time PCR analysis.
Data are presented as the percentage of input. The following primers were used for
CXCR4 ChIP qPCR analysis: 5′- TTCCAGTGGCTGCATGTGTC-3′ and 5′-
CAGACAATGTAACTCGCTCC-3′. The antibodies used for ChIP assay were as
follows: anti-p65 acetyl K310 (ab19870, Abcam), anti-H3K9ac (06-942, Millipore,
Kankakee, IL, USA), and anti-H4K16ac (ab109463, Abcam).
Immunoprecipitation and immunoblotting. Immunoprecipitation assay was
performed to verify the endogenous interaction between HDAC5 and acetylated
p6516. 293T Cells (ATCC CRL-3216) were lysed using immunoprecipitation buffer
containing protease inhibitor cocktail. Cell lysates were then centrifuged at 4 °C,
13,000 × g for 15 min, and the supernatants were incubated with anti-HDAC5
antibody (Cell Signaling Technology, Beverly, MA, USA, D1J7V, 20458) or IgG
control in 1:100 dilution, followed by incubation withprotein A agarose beads (Cell
Signaling Technology). Immunoprecipitates were washed and subjected to
immunoblotting analysis using anti-p65 acetyl K310 (Abcam) and anti-actin
(Sigma, A3853). Uncropped images of western blottings are shown in Supple-
mentary Figure 7.
RNA extraction and real-time PCR. RNA was extracted using the RNeasy Mini
Kit following the manufacturer’s protocol (74104, QIAGEN, Valencia, CA,
USA). Total RNA was reverse transcribed using Superscript III First-Strand
Synthesis System (Thermo Fisher, Waltham, MA, USA). Quantitative real-time
PCR reactions were performed using the QuantiTect SYBR Green PCR Kit
(204143, QIAGEN) and a Stratagene Mx3000p PCR System. GAPDH mRNA
levels were used as the internal control. mRNA expression levels were normal-
ized to GAPDH mRNA levels and shown as arbitrary units relative to vehicle
control (set as 1). The primer sequences for CXCR4 were: 5′- TCTATGTTGG
CGTCTGGATCC-3′ and 5′-CTTGGAGTGTGACAGCTTGG-3′. GAPDH pri-
mer sequences were: 5′-TTCGTCATGGGTGTGAACCA-3′ and 5′- TGGCAGT
GATGGCATGGACT-3′.
RNA-seq and analysis. CB CD34+ cells were pretreated with vehicle control or
LMK235 for 16 h. RNA was extracted using the RNeasy Mini Kit (QIAGEN).
RNA-seq was conducted using Illumina Nextseq 500 in the Center for Medical
Genomics at Indiana University School of Medicine. For RNA-seq analysis, we
used FastQC to examine the quality of RNA-seq reads then mapped all sequences
past the quality control to the human genome (UCSC hg19) by STAR RNA-seq
aligner50. Uniquely mapped sequencing reads were assigned to genes according to
the refGene from UCSC (hg19) with the package of Subread, featureCounts51. The
gene expression was normalized by the method of trimmed mean of M values.
EdgeR52 was adopted for differential expression analysis by paired comparison
between each paired replicates of treatment and control. P-value of each gene was
adjusted by multiple test correction via false discovery rate (FDR) estimation.
Differentially expressed gene (DEG) was determined if its FDR-adjusted p-value
was less than 0.01, and the fold change was greater than 1.7 (upregulated) or less
than 0.588 (downregulated). Only DEG whose average count-per-million for wild-
type samples is larger than 2 was took into account for biological functional
analysis by using DAVID functional annotation analysis (http://david.abcc.ncifcrf.
gov/home.jsp v6.8)53,54.
Statistical analysis. Statistical analysis was conducted using Microsoft Excel and
GraphPad Prism. Two-tailed Student’s t-test was used for statistical analysis
between two groups. One-way analysis of variance with Tukey’s multiple com-
parison test was performed to compare the difference among more than two
groups where indicated. P values are designated as *p < 0.05, **p < 0.01, ***p <
0.001. Error bars represent SEM unless otherwise stated.
Data availability. RNA-seq data have been deposited in the GEO database under
accession number GSE110736. The authors declare that all data supporting the
findings of this study are available within the article and its supplementary
information files or from the corresponding author upon reasonable request.
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